Market Place
Sourcing Support
Viking Therapeutics Ph 2b Results of VK2809 at Liver Meeting 2024
19 Nov 2024 //
PR NEWSWIRE
Viking Therapeutics to Present VOYAGE Study Data at Liver Meeting
12 Nov 2024 //
PR NEWSWIRE
Viking oral obesity med posts 6.8% weight loss for highest dose
04 Nov 2024 //
FIERCE BIOTECH
Viking Therapeutics Reports VK2735 Data at ObesityWeek® 2024
04 Nov 2024 //
PR NEWSWIRE
Viking Therapeutics Highlights VK2735 Data at ObesityWeek® 2024
28 Oct 2024 //
PR NEWSWIRE
Viking Therapeutics Reports Q3 2024 Financial Results And Update
23 Oct 2024 //
PR NEWSWIRE
Viking Therapeutics To Financial Report Q3 2024 Results On Oct 23
16 Oct 2024 //
PR NEWSWIRE
Viking Therapeutics Announces Results From Phase 1b Trial
09 Oct 2024 //
PR NEWSWIRE
Weight-loss market to see 16 new drugs by 2029, report estimates
11 Sep 2024 //
EXPRESSPHARMA
Viking to push obesity drug to Phase 3 in bid to reach market faster
24 Jul 2024 //
ENDPTS
Viking`s MASH drug scores where Madrigal`s didn`t
05 Jun 2024 //
FIERCE BIOTECH
Viking Therapeutics: Positive VK2809 Data In NASH Patients At 52 Weeks
04 Jun 2024 //
PR NEWSWIRE
Viking Reports Q1 2024 Results, Corporate Update
24 Apr 2024 //
PR NEWSWIRE
Viking Therapeutics to Report Q1 2024 Results on April 24
17 Apr 2024 //
PR NEWSWIRE
Biotech naming trends bypass `buzzwords and business speak`
16 Apr 2024 //
FIERCE BIOTECH
Viking Therapeutics` weight-loss tablet shows promise in small study
27 Mar 2024 //
REUTERS
Viking Announces Results from Phase 1 Trial of Oral Tablet Formulation
26 Mar 2024 //
PR NEWSWIRE
Viking Therapeutics Announces Closing of Public Offering of Common Stock
04 Mar 2024 //
PR NEWSWIRE
Truist raises Viking Therapeutics stock target to $120 on GLP1 profile
29 Feb 2024 //
PRESS RELEASE
Viking Announces Pricing of $550 Million Public Offering of Common Stock
28 Feb 2024 //
PR NEWSWIRE
Viking data suggest obesity drug could rival Zepbound, Wegovy
28 Feb 2024 //
BIOPHARMA DIVE
Viking Therapeutics Announces Proposed Public Offering of Common Stock
27 Feb 2024 //
PR NEWSWIRE
Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
07 Feb 2024 //
PR NEWSWIRE
Viking to Report Financial Results for Fourth Quarter and Year-End 2023
31 Jan 2024 //
PR NEWSWIRE
Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809
13 Nov 2023 //
PR NEWSWIRE
Viking Therapeutics Reports Third Quarter 2023 Financial Results
25 Oct 2023 //
PR NEWSWIRE
Viking Announces Completion of Enrollment in Ph 2 Trial of Dual GLP-1/GIP VK2735
23 Oct 2023 //
PR NEWSWIRE
Viking to Report Financial Results for Third Quarter 2023 on October 25, 2023
18 Oct 2023 //
PR NEWSWIRE
Viking Therapeutics to Participate at Upcoming Investor Conferences
07 Sep 2023 //
PR NEWSWIRE
Viking Announces Initiation of Phase 2 Trial of Dual GLP-1/GIP Receptor VK2735
06 Sep 2023 //
PR NEWSWIRE
Prospective NASH market flips from failure to overcrowded
10 Aug 2023 //
FIERCE BIOTECH
Viking Therapeutics Reports Second Quarter 2023 Financial Results
26 Jul 2023 //
PR NEWSWIRE
Viking sails higher after NASH therapy slays midphase test
16 May 2023 //
FIERCE BIOTECH
Viking Therapeutics Reports 1Q 2023 FYR and Provides Corporate Update
26 Apr 2023 //
PR NEWSWIRE
Viking Announces Pricing of $250 Million Public Offering of Common Stock
29 Mar 2023 //
PRESS RELEASE
Viking joins obesity drug race after promising early trial data
29 Mar 2023 //
REUTERS
Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results
08 Feb 2023 //
PR NEWSWIRE
Viking to Report Financial Results for Fourth Quarter on February 8, 2023
01 Feb 2023 //
PR NEWSWIRE
Viking Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809
09 Jan 2023 //
PR NEWSWIRE
Viking accuses Chinese co of stealing fatty liver disease drug secrets
30 Dec 2022 //
REUTERS
This Stock That Tripled in 2022 Could Rocket Even Higher in 2023
26 Dec 2022 //
FOOL
Viking` stock rallies after Madrigal shares positive data about its liver drug
19 Dec 2022 //
MARKETWATCH
Viking Therapeutics Reports Third Quarter 2022 Financial Results
26 Oct 2022 //
PRNEWSWIRE
Microcap Viking gets a reprieve as FDA lifts hold on PhII study
20 Jul 2022 //
ENDPTS
Viking eports Q1 2022 Financial Results and Provides Corporate Update
27 Apr 2022 //
PRNEWSWIRE
Viking Therapeutics to Report Financial Results for Q1 2022
20 Apr 2022 //
PRNEWSWIRE
FDA hits Viking clinical hold over mix-up in phase of trial
25 Jan 2022 //
FIERCEBIOTECH
Viking Reports Q3 2021 Financial Results and Provides Corporate Update
03 Nov 2021 //
PRNEWSWIRE
Viking Therapeutics Presents Preclinical Data on Novel Dual GLP-1/GIP Agonists
01 Nov 2021 //
PRNEWSWIRE
Viking to Present Preclinical Data on Novel Dual GLP-1/GIP Agonists
25 Oct 2021 //
PRNEWSWIRE
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of VK0214
17 Jun 2021 //
PRNEWSWIRE
Viking to Present at 20th Annual Needham Virtual Healthcare Conference
07 Apr 2021 //
PRNEWSWIRE
Viking Therapeutics Announces Senior Management Team Appointments
06 Jan 2021 //
PRNEWSWIRE
Viking Therapeutics Presents New Data from Phase 2 Study of VK2809
27 Aug 2020 //
PRNEWSWIRE
Viking Therapeutics to Present New Data from Phase 2 Study of VK2809
19 Aug 2020 //
PRNEWSWIRE
Viking Therapeutics to Participate in Upcoming Investor Conferences
28 Apr 2020 //
PR NEWSWIRE
Viking Therapeutics Announces Initiation of Phase 2b VOYAGE Study
19 Nov 2019 //
PR NEWSWIRE
Viking Therapeutics Announces Initiation of Phase 2b VOYAGE Study
18 Nov 2019 //
PR NEWSWIRE
Researchers Target NAFLD, NASH Using Lab-on-a-Chip Technology
30 Aug 2019 //
BIOSPACE
Viking Therapeutics Presents New Data from Phase 2 Study of VK2809
11 Apr 2019 //
PR NEWSWIRE
